Multiple Myeloma News

Pesticides Linked to Precancerous Blood Disorder (June 24, 2009)

Pesticides Linked to Precancerous Blood Disorder Individuals who apply pesticides to crops are twice as likely as the general population to develop a precancerous blood disorder called MGUS (monoclonal gammopathy of undetermined significance), which can... Continue Reading

Formaldehyde Exposure May Increase Risk of Blood and Lymphatic Cancers (June 23, 2009)

Formaldehyde Exposure May Increase Risk of Blood and Lymphatic Cancers Industrial workers who are exposed to formaldehyde may be at an increased risk of dying from blood and lymphatic cancers, particularly myeloid leukemia but also Hodgkin’s lymphoma... Continue Reading

Thalomid® – Prolongs Survival in Multiple Myeloma (April 27, 2009)

One year of treatment with Thalomid® (thalidomide) and prednisone after a single autologous stem cell transplant prolongs survival in patients with newly diagnosed multiple myeloma, according to the results of a study published in the Journal of Clinical... Continue Reading

Green Tea May Negate the Benefits of Velcade® (March 31, 2009)

Consumption of green tea may be contraindicated for patients who are receiving treatment with Velcade® (bortezomib), as the polyphenols in green tea may actually negate the therapeutic benefits of the drug, according to the results of a study published... Continue Reading

Multiple Myeloma Overview (March 18, 2009)

Overview Multiple myeloma is a cancer of plasma cells. Plasma cells are a special type of white blood cell that are part of the body’s immune system. Plasma cells normally live in the bone marrow and make proteins, called antibodies, that circulate... Continue Reading

Velcade® Combinations for Newly Diagnosed Patients with Multiple Myeloma at ASH 2008 (February 18, 2009)

Velcade® Combinations for Newly Diagnosed Patients with Multiple Myeloma at ASH 2008 At the 2008 meeting of the American Society of Hematology (ASH) in December in San Francisco, there were several oral presentations on the outcomes of newly diagnosed... Continue Reading

Velcade® Combinations for Newly Diagnosed Patients with Multiple Myeloma at ASH 2008 (February 18, 2009)

Velcade® Combinations for Newly Diagnosed Patients with Multiple Myeloma at ASH 2008 At the 2008 meeting of the American Society of Hematology (ASH) in December in San Francisco, there were several oral presentations on the outcomes of newly diagnosed... Continue Reading

Revlimid® Combinations for Newly Diagnosed Multiple Myeloma Reported at ASH 2008 (February 18, 2009)

Revlimid® Combinations for Newly Diagnosed Multiple Myeloma Reported at ASH 2008 At the 2008 meeting of the American Society of Hematology (ASH) in December, there were several oral presentations on the outcomes of newly diagnosed patients with multiple... Continue Reading

Revlimid® Combinations for Newly Diagnosed Multiple Myeloma Reported at ASH 2008 (February 18, 2009)

Revlimid® Combinations for Newly Diagnosed Multiple Myeloma Reported at ASH 2008 At the 2008 meeting of the American Society of Hematology (ASH) in December, there were several oral presentations on the outcomes of newly diagnosed patients with multiple... Continue Reading

Understanding Stem Cell Transplants (February 6, 2009)

High-dose chemotherapy and bone marrow or blood stem cell transplantation (SCT) remains the best treatment available for selected patients with certain types of leukemia. The SCT process was developed more than 36 years ago and was considered such a major... Continue Reading